| アブストラクト | beta-Adrenergic receptor blockers (beta-blockers) are used to treat hypertension, ischemic heart disease, chronic heart failure, and tachyarrhythmia. The main side effects of treatment include bradycardia, atrioventricular block, and hypotension. Bradycardia may result in pacemaker implantation as well as the discontinuation of beta-blockers. Bradycardia is difficult to confirm at a single institution because it diagnosed only by symptoms when electrocardiogram (ECG) are not routinely performed. Previous studies reported an increase in bradycardia in heart failure patients treated with beta-blockers; however, limited information is currently available for non-heart failure patients. Bradycardia induced by beta-blockers has not yet been comprehensively examined. Therefore, the present study investigated data on the incidence and duration of bradyarrhythmia caused by beta-blockers using the Japanese Adverse Drug Event Report database (JADER). Cases of adverse effects associated with this medication were extracted from JADER and Fisher's exact test was performed to assess whether each beta-blocker caused bradyarrhythmia. In addition, only data from patients who reported bradyarrhythmia after beta-blocker treatment were extracted, and the Weibull distribution was used to analyze the time-to-onset of bradyarrhythmia. Thirteen beta-blockers caused bradyarrhythmia and signals were observed for 12 drugs, except nadolol. Bradyarrhythmia induced by oral beta-blockers was more likely to be of the early failure type, and developed within 2 months of treatment initiation with most beta-blockers. A comprehensive analysis of bradyarrhythmia with beta-blockers suggests that careful monitoring is needed, particularly early in the initiation of treatment. |
|---|
